Literature DB >> 21796448

The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases.

Catarina Eloy1, Joana Santos, Paula Soares, Manuel Sobrinho-Simões.   

Abstract

Prognostic factors indicative of papillary thyroid carcinoma (PTC) aggressive behaviour remain incompletely established partially due to the different composition of the series on record regarding the relative proportion of classic PTC (CPTC) and follicular variant PTC (FVPTC) subtypes. Several clinico-morphological features of PTC, together with the occurrence of BRAF mutations, are still not fully accepted as markers of aggressiveness. In the present clinico-pathological study of a series of 75 CPTC and FVPTC cases, we evaluated the relative contribution of the morphological features of the tumours and their BRAF and N-RAS status for the occurrence of nodal metastases. The morphological features most closely related to the occurrence of nodal metastases were extra-thyroid extension and poorly circumscribed growth pattern, in both CPTC and FVPTC. Additional features significantly associated to nodal metastases were multicentricity in the CPTC and vascular invasion in the FVPTC group. BRAF V600E mutation was detected in 29% of tumours, 41% of CPTC and 16% of FVPTC; N-RAS Q61R mutation was detected in 6% of tumours, 3% of CPTC and 10% of FVPTC. BRAF mutation was significantly more frequent in the CPTC group and in females, and it was detected only in patients older than 20 years, suggesting a late tumourigenic effect in the development of PTC. BRAF mutation was not significantly associated to any of the other studied features related to aggressiveness or nodal metastases. These results highlight the importance of infiltrative growth pattern and invasiveness over the presence of BRAF mutation in classic and follicular variant PTC for the development of nodal metastases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796448     DOI: 10.1007/s00428-011-1133-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  50 in total

1.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

Authors:  Y E Nikiforov; J M Rowland; K E Bove; H Monforte-Munoz; J A Fagin
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

Review 2.  Molecular pathology of well-differentiated thyroid carcinomas.

Authors:  Manuel Sobrinho-Simões; Ana Preto; Ana Sofia Rocha; Patrícia Castro; Valdemar Máximo; Elsa Fonseca; Paula Soares
Journal:  Virchows Arch       Date:  2005-09-28       Impact factor: 4.064

Review 3.  BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.

Authors:  Kam-Tsun Tang; Chen-Hsen Lee
Journal:  J Chin Med Assoc       Date:  2010-03       Impact factor: 2.743

4.  Cancer: Small papillary thyroid cancers--is BRAF of prognostic value?

Authors:  Paula Soares; Manuel Sobrinho-Simões
Journal:  Nat Rev Endocrinol       Date:  2011-01       Impact factor: 43.330

5.  Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.

Authors:  Jeffrey Liu; Bhuvanesh Singh; Giovanni Tallini; Diane L Carlson; Nora Katabi; Ashok Shaha; R Michael Tuttle; Ronald A Ghossein
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

6.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

7.  Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population.

Authors:  Kyung Hee Kim; Dong Wook Kang; Seong Ho Kim; In Ock Seong; Dae Young Kang
Journal:  Yonsei Med J       Date:  2004-10-31       Impact factor: 2.759

8.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

9.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

Review 10.  Molecular genetics of papillary thyroid carcinoma: great expectations.

Authors:  Vítor Trovisco; Paula Soares; Ana Preto; Patrícia Castro; Valdemar Máximo; Manuel Sobrinho-Simões
Journal:  Arq Bras Endocrinol Metabol       Date:  2007-07
View more
  17 in total

1.  Comparison of the clinicopathological behavior of the follicular variant of papillary thyroid carcinoma and classical papillary thyroid carcinoma: A systematic review and meta-analysis.

Authors:  Jing Yang; Yanping Gong; Shuping Yan; Qingquan Shi; Jingqiang Zhu; Zhihui Li; Qiang Chen; Rixiang Gong
Journal:  Mol Clin Oncol       Date:  2015-04-06

2.  TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.

Authors:  Gustavo C Penna; Ana Pestana; José Manuel Cameselle; Denise Momesso; Fernanda Accioly de Andrade; Ana Paula Aguiar Vidal; Mario Lucio Araujo Junior; Miguel Melo; Priscila Valverde Fernandes; Rossana Corbo; Mario Vaisman; Manuel Sobrinho-Simões; Paula Soares; Fernanda Vaisman
Journal:  Endocrine       Date:  2018-06-15       Impact factor: 3.633

Review 3.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

4.  Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma.

Authors:  C Eloy; J Santos; P Soares; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  2011-11-12       Impact factor: 4.064

5.  Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.

Authors:  Ann E Walts; James M Mirocha; Shikha Bose
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-22       Impact factor: 4.553

6.  TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.

Authors:  C Eloy; J Santos; J Cameselle-Teijeiro; P Soares; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  2012-04-20       Impact factor: 4.064

7.  Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.

Authors:  Min Ji Jeon; Sung Min Chun; Ji-Young Lee; Kyeong Woon Choi; Deokhoon Kim; Tae Yong Kim; Se Jin Jang; Won Bae Kim; Young Kee Shong; Dong Eun Song; Won Gu Kim
Journal:  Endocrine       Date:  2019-01-15       Impact factor: 3.633

8.  Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study.

Authors:  Renu K Virk; Constantine G A Theoharis; Avinash Prasad; David Chhieng; Manju L Prasad
Journal:  Virchows Arch       Date:  2014-02-19       Impact factor: 4.064

9.  The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.

Authors:  Daniele Barbaro; Roberto Mario Incensati; Gabriele Materazzi; Giuseppe Boni; Mariano Grosso; Erica Panicucci; Paola Lapi; Cristina Pasquini; Paolo Miccoli
Journal:  Endocrine       Date:  2013-08-08       Impact factor: 3.633

10.  Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.

Authors:  Jing-Yong Song; Shi-Ran Sun; Fang Dong; Tao Huang; Bin Wu; Jing Zhou
Journal:  Curr Med Sci       Date:  2018-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.